To increase the number of manufacturers registered under the Controlled Substances Act to manufacture cannabis for legitimate research purposes, to authorize health care providers of the Department of Veterans Affairs to provide recommendations to veterans regarding participation in federally-approved cannabis clinical trials, and for other purposes.
Actions Overview (1)
Date
Actions Overview
04/26/2018
Introduced in House
04/26/2018 Introduced in House
All Actions (7)
Date
All Actions
09/13/2018
Ordered to be Reported (Amended) by Voice Vote. Action By: Committee on the Judiciary
05/22/2018
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations. Action By: Committee on the Judiciary
04/26/2018
Referred to the Subcommittee on Health. Action By: Committee on Veterans' Affairs
04/26/2018
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. Action By: House of Representatives
04/26/2018
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. Action By: House of Representatives
04/26/2018
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. Action By: House of Representatives
04/26/2018
Introduced in House Action By: House of Representatives
09/13/2018 Ordered to be Reported (Amended) by Voice Vote.
05/22/2018 Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
04/26/2018 Referred to the Subcommittee on Health.
04/26/2018 Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
04/26/2018 Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
04/26/2018 Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.
Committee / Subcommittee
Date
Activity
Reports
House Energy and Commerce
04/26/2018
Referred to
House Judiciary
04/26/2018
Referred to
House Judiciary Subcommittee on Crime, Terrorism, Homeland Security, and Investigations
05/22/2018
Referred to
House Veterans' Affairs
04/26/2018
Referred to
House Veterans' Affairs Subcommittee on Health
04/26/2018
Referred to
Related Bills (0)
No related bill information was received for H.R.5634.
This bill amends the Controlled Substances Act to establish a new, separate registration process for manufacturers of cannabis for research.
The Drug Enforcement Administration must assess whether there is an adequate and uninterrupted supply of research cannabis and register additional manufacturers.
All Summaries (1)
Shown Here: Introduced in House (04/26/2018)
Medical Cannabis Research Act of 2018
This bill amends the Controlled Substances Act to establish a new, separate registration process for manufacturers of cannabis for research.
The Drug Enforcement Administration must assess whether there is an adequate and uninterrupted supply of research cannabis and register additional manufacturers.